Insider Transaction Report for Acumen Pharmaceuticals, Inc.

Laura Stoppel, a director at Acumen Pharmaceuticals, Inc. (ABOS), reported a transaction on June 3, 2026. Stoppel acquired 35,500 shares of Common Stock and 53,250 stock options. These acquisitions are part of a restricted stock unit (RSU) award, with full vesting expected by the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, contingent upon continuous service. The options have an exercise price of $2.29 and expire on June 3, 2036. Stoppel holds these securities for the benefit of RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund II, L.P., and a separately managed account, disclaiming beneficial ownership due to an arrangement with RA Capital Management, L.P. where proceeds will offset advisory fees.